In the European Union, the combination is indicated for the treatment of COVID-19 in people aged twelve years of age and older weighing at least who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID-19; and for the prevention of COVID-19 in people aged twelve years of age and older weighing at least .
Casirivimab/imdevimab
Atoltivimab/maftivimab/odesivimab
Tixagevimab/cilgavimab
Bamlanivimab/etesevimab
Obiltoxaximab
Regdanvimab
Valoctocogene roxaparvovec
Odesivimab